C12N 2740/13034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/13034 (Use of virus or viral component as vaccine) appears on 50 US grants and 74 published applications in this corpus.
Search patents in C12N- Granted patents
- 50
- Published applications
- 74
- Assignees
- 44
- Inventors
- 136
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 2 |
| 2003 | 0 | 2 |
| 2004 | 1 | 2 |
| 2005 | 2 | 2 |
| 2006 | 0 | 3 |
| 2007 | 1 | 1 |
| 2008 | 1 | 4 |
| 2009 | 3 | 3 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 2 | 1 |
| 2014 | 1 | 3 |
| 2015 | 2 | 2 |
| 2016 | 0 | 2 |
| 2017 | 3 | 1 |
| 2018 | 3 | 3 |
| 2019 | 3 | 2 |
| 2020 | 1 | 3 |
| 2021 | 1 | 10 |
| 2022 | 4 | 4 |
| 2023 | 3 | 5 |
| 2024 | 3 | 9 |
| 2025 | 5 | 3 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Adjuvant compositions13 Jan 2026US 12,521,433 B2Zoetis Services LLC
- Compositions and methods for inducing immune responses19 Aug 2025US 12,390,524 B2Arcturus Therapeutics, Inc.
- IL2 agonists and methods of use thereof3 Jun 2025US 12,319,724 B2Regeneron Pharmaceuticals, Inc.
- Coronavirus vaccine compositions and methods11 Feb 2025US 12,220,455 B2Arcturus Therapeutics, Inc.
- Compositions and methods for inducing immune responses12 Mar 2026US 2026/0069677 A1Arcturus Therapeutics, Inc.
- Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use5 Feb 2026US 2026/0035415 A1Twilight Bioscience, Inc.
- Immunotherapeutic compositions for treatment of glioblastoma multiforme18 Dec 2025US 2025/0381266 A1Variation Biotechnologies Inc.
- Coronavirus vaccine compositions and methods22 May 2025US 2025/0161434 A1Arcturus Therapeutics, Inc.
- Novel il2 agonists and methods of use thereof30 Jan 2025US 2025/0034224 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Regulation of systemic immune responses utilizing cytokines and antigens59US 5,904,920 AThe Johns Hopkins University School of Medicine · 1999
- Vaccines containing a saponin and a sterol47US 6,846,489 B1SmithKline Beecham Biologicals s.a. · 2005
- Enterically administered recombinant poxvirus vaccines32US 5,676,950 AUniversity of Florida · 1997
- Defective viral vaccine particles obtained in vivo or ex vivo31US 6,140,114 AUniversite Pierre et Marie Curie (Paris VI) · 2000
- Feline leukemia virus protein vaccines17US 4,876,089 AChiron Corporation · 1989